A multistage oral delivery system of PTX for improving oral bioavailability and enhancing anticancer efficacy

References

• Pilleron S, Sarfati D, Janssen-Heijnen M, et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144(1):49–58.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628.
   PubMed Web of Science ®Google Scholar
• El Saghir NS, Tfayli A, Hatoum HA, et al. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol. 2011;80(3):433–449.
   PubMed Web of Science ®Google Scholar
• Lin ZQ, Gao W, Hu HX, et al. Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: high drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity. J Control Release. 2014;174:161–170.
   PubMed Web of Science ®Google Scholar
• Akhlaghi SP, Saremi S, Ostad SN, et al. Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines. Nanomedicine. 2010;6(5):689–697.
   PubMed Web of Science ®Google Scholar
• Luo T, Wang J, Yin YC, et al. Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res. 2010;12(1):R8.
   PubMed Web of Science ®Google Scholar
• Luo JW, Zhang T, Zhang Q, et al. A novel injectable phospholipid gel co-loaded with doxorubicin and bromotetrandrine for resistant breast cancer treatment by intratumoral injection. Colloids Surf B Biointerf. 2016;140:538–547.
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Niu SW, Williams GR, et al. Dual-responsive nanoparticles based on chitosan for enhanced breast cancer therapy. Carbohydr Polym. 2019;221:84–93.
   PubMed Web of Science ®Google Scholar
• Ma P, Benhabbour SR, Feng L, et al. 2′-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer. Cancer Lett. 2013;334(2):253–262.
   PubMed Web of Science ®Google Scholar
• Chakravarthi SS, De SJ, Miller DW, et al. Comparison of anti-tumor efficacy of paclitaxel delivered in nano- and microparticles. Int J Pharm. 2010;383(1–2):37–44.
   PubMed Web of Science ®Google Scholar
• Hamaguchi T, Matsumura Y, Suzuki M, et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005;92(7):1240–1246.
   PubMed Web of Science ®Google Scholar
• Yang T, Cui FD, Choi MK, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338(1–2):317–326.
   PubMed Web of Science ®Google Scholar
• Kessel D, Woodburn K, Decker D, et al. Fractionation of cremophor el delineates components responsible for plasma-lipoprotein alterations and multidrug-resistance reversal. Oncol Res. 1995;7(5):207–212.
   PubMed Web of Science ®Google Scholar
• Rege BD, Kao JPY, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci. 2002;16(4–5):237–246.
   PubMed Web of Science ®Google Scholar
• Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharmaceut Res. 1996;13(4):528–534.
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19(13):1946–2025.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V-B. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–162.
   PubMed Web of Science ®Google Scholar
• Hendrikx JJMA, Lagas JS, Rosing H, et al. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer. 2013;132(10):2439–2447.
   PubMed Web of Science ®Google Scholar
• Wei N, Sun H, Wang FP, et al. H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein. Cancer Chemother Pharmacol. 2011;67(5):1017–1025.
   PubMed Web of Science ®Google Scholar
• Wang FH, Zhang DR, Zhang Q, et al. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials. 2011;32(35):9444–9456.
   PubMed Web of Science ®Google Scholar
• Zhang FR, Wang XY, Xu XT, et al. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells. Eur J Pharm Sci. 2016;92:11–21.
   PubMed Web of Science ®Google Scholar
• Zhang T, Luo JW, Fu Y, et al. Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer. Colloids Surf B Biointerf. 2017;150:89–97.
   PubMed Web of Science ®Google Scholar
• Cao X, Luo JW, Gong T, et al. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. Mol Pharmac. 2015;12(1):274–286.
   PubMed Web of Science ®Google Scholar
• Song X, Wan ZY, Chen TJ, et al. Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment. Biomaterials. 2016;108:44–56.
   PubMed Web of Science ®Google Scholar
• Sadekar S, Thiagarajan G, Bartlett K, et al. Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin. Int J Pharm. 2013;456(1):175–185.
   PubMed Web of Science ®Google Scholar
• Chen TE, Tu LX, Wang G, et al. Multi-functional chitosan polymeric micelles as oral paclitaxel delivery systems for enhanced bioavailability and anti-tumor efficacy. Int J Pharm. 2020;578:119105.
   PubMedGoogle Scholar
• Wang ZJ, Xu YH, Meng XN, et al. Suppression of c-Myc is involved in multi-walled carbon nanotubes’ down-regulation of ATP-binding cassette transporters in human colon adenocarcinoma cells. Toxicol Appl Pharmacol. 2015;282(1):42–51.
   PubMed Web of Science ®Google Scholar
• Hu M, Zhang JJ, Ding R, et al. Improved oral bioavailability and therapeutic efficacy of dabigatran etexilate via Soluplus-TPGS binary mixed micelles system. Drug Dev Ind Pharm. 2017;43(4):687–697.
   PubMed Web of Science ®Google Scholar
• Atherton E. Determinations of size of particles with the electron microscope. Nature. 1953;171(4347):350–351.
   PubMed Web of Science ®Google Scholar
• Devani M, Ashford M, Craig DQM. The emulsification and solubilisation properties of polyglycolysed oils in self-emulsifying formulations. J Pharm Pharmacol. 2004;56(3):307–316.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hu Y, Xiao D, et al. Stabilization of Notch1 by the Hsp90 chaperone is crucial for T-cell leukemogenesis. Clin Cancer Res. 2017;23(14):3834–3846.
   PubMed Web of Science ®Google Scholar
• Bao LL, Haque A, Jackson K, et al. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol. 2011;178(2):838–852.
   PubMed Web of Science ®Google Scholar
• Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 1989;96(3):736–749.
   PubMed Web of Science ®Google Scholar
• Du GJ, Song ZH, Lin HH, et al. Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells. Biochem Biophs Res Co. 2008;372(3):497–502.
   PubMed Web of Science ®Google Scholar
• Artursson P, Karlsson JJB, Communications b. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;175(3):880–885.
   PubMed Web of Science ®Google Scholar
• Mandagere AK, Thompson TN, Hwang KK. Graphical model for estimating oral bioavailability of drugs in humans and other species from their caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem. 2002;45(2):304–311.
   PubMed Web of Science ®Google Scholar
• Yuan H, Lu LJ, Du YZ, et al. Stearic acid-g-chitosan polymeric micelle for oral drug delivery: in vitro transport and in vivo absorption. Mol Pharm. 2011;8(1):225–238.
   PubMed Web of Science ®Google Scholar
• Liu XD, Sun H, Liu GT. 5-Bromotetrandrine enhances the sensitivity of doxorubicin-induced apoptosis in intrinsic resistant human hepatic cancer Bel7402 cells. Cancer Lett. 2010;292(1):24–31.
   PubMed Web of Science ®Google Scholar
• Ho P-Y, Yeh T-K, Yao H-T, et al. Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. Int J Pharm. 2008;359(1–2):174–181.
   PubMedGoogle Scholar
• Liu N, Tan YN, Hu YW, et al. A54 peptide modified and redox-responsive glucolipid conjugate micelles for intracellular delivery of doxorubicin in hepatocarcinoma therapy. ACS Appl Mater Interfaces. 2016;8(48):33148–33156.
   PubMed Web of Science ®Google Scholar
• Kadler KE, Hill A, Canty-Laird EG. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol. 2008;20(5):495–501.
   PubMed Web of Science ®Google Scholar
• Loeffler M, Kruger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006;116(7):1955–1962.
   PubMed Web of Science ®Google Scholar
• Attili-Qadri S, Karra N, Nemirovski A, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci USA. 2013;110(43):17498–17503.
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Garcion E, et al. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009;140(2):174–181.
   PubMed Web of Science ®Google Scholar
• Zhang B, Xue AY, Zhang C, et al. Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel. Pharmazie. 2016;71(6):320–326.
   PubMed Web of Science ®Google Scholar
• Binkhathlan Z, Shayeganpour A, Brocks DR, et al. Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin. Eur J Pharm Biopharm. 2012;81(1):142–148.
   PubMed Web of Science ®Google Scholar
• Choi DH, Choi JS, Li C, et al. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. Pharmacol Rep. 2011;63(6):1574–1582.
   PubMed Web of Science ®Google Scholar
• Minocha M, Khurana V, Qin B, et al. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. Int J Pharm. 2012;434(1–2):306–314.
   PubMed Web of Science ®Google Scholar